How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,681 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. (Abstract)

Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversible suppression of ovarian sex hormones, may reduce fibroid-associated bleeding.We conducted two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 and UF-2]) to evaluate (...) heavy menstrual bleeding in women with uterine fibroids. (Funded by AbbVie; Elaris UF-1 and Elaris UF-2 ClinicalTrials.gov numbers, NCT02654054 and NCT02691494.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM

22. Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids. (Abstract)

Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids. Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18-64 years

2019 Current medical research and opinion

23. Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. (Full text)

Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. Uterine fibroids may decrease quality of life in a significant proportion of affected women. Myomectomy offers a uterine-sparing treatment option for patients with uterine fibroids that can be performed abdominally, laparoscopically (with or without robotic assistance), and hysteroscopically. Quality of life information using validated measures for different myomectomy routes, especially (...) hysteroscopic myomectomy, is limited.To compare women's perception of their short-term health-related quality of life measures and reported time to return to usual activities and return to work for different routes of myomectomy.Comparing Options for Management: Patient-centered Results for Uterine Fibroids (COMPARE-UF) is a prospective nationwide fibroid registry that enrolled premenopausal women seeking treatment for uterine fibroids at 8 clinical sites. For this analysis, we included women undergoing

2020 American Journal of Obstetrics and Gynecology PubMed abstract

24. Management of Uterine Fibroids

Management of Uterine Fibroids Comparative Effectiveness Review Number 195 Management of Uterine Fibroids eComparative Effectiveness Review Number 195 Management of Uterine Fibroids Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00003-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, TN Investigators: Katherine E. Hartmann, M.D., Ph.D. Christopher (...) Fonnesbeck, Ph.D. Tanya Surawicz, M.P.H. Shanthi Krishnaswami, M.B.B.S., M.P.H. Jeffrey C. Andrews, M.D. Jo Ellen Wilson, M.D., M.P.H. Digna Velez-Edwards, Ph.D., M.S. Shannon Kugley, M.L.I.S. Nila A. Sathe, M.A., M.L.I.S. AHRQ Publication No. 17(18)-EHC028-EF December 2017 Key Messages Purpose of Review To review treatment effectiveness and the risk of leiomyosarcoma (LMS) in women with fibroids. Key Messages • Gonadotropin-releasing hormone (GnRH) agonists, mifepristone, ulipristal, and uterine artery

2017 Effective Health Care Program (AHRQ)

25. Practice Advisory: Management of Uterine Leiomyomas (Fibroids)

Practice Advisory: Management of Uterine Leiomyomas (Fibroids) Page Not Found | ACOG Clinical Information Practice Management Career Support Education & Events Advocacy Topics Education Events Clinical Topics Hi, Education Events Clinical Topics Page Not Found The page you're trying to access is currently unavailable. It may have moved during our website redesign. Try searching below or visiting our to find the resource you need. ACOG Sites ACOG Sites American College of Obstetricians

2017 American College of Obstetricians and Gynecologists

26. Hysteroscopic morcellation of uterine fibroids (IPG486)

Hysteroscopic morcellation of uterine fibroids (IPG486) Hysteroscopic morcellation of uterine fibroids | Guidance | NICE Hysteroscopic morcellation of uterine fibroids Interventional procedures guidance [IPG486] Published date: April 2014 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

27. Ulipristal acetate (Esmya) - uterine fibroids

Ulipristal acetate (Esmya) - uterine fibroids Final Appraisal Recommendation Advice No: 0716 – March 2016 Ulipristal acetate (Esmya ® ) 5 mg tablets Submission by Gedeon Richter UK Ltd Additional notes: ? Please refer to the Summary of Product Characteristics (SPC) for the full licensed indication and monitoring requirements. ? This advice incorporates and replaces the existing AWMSG recommendation on ulipristal acetate for the pre-operative treatment of moderate to severe symptoms of uterine (...) tablets. March 2016. Recommendation of AWMSG Ulipristal acetate (Esmya ® ) is recommended as an option for use within NHS Wales for the intermittent treatment or pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

2016 All Wales Medicines Strategy Group

28. Laparoscopic Myomectomy with Temporary Bilateral Uterine Artery and Utero-Ovarian Vessels Occlusion Compared with Traditional Surgery for Uterine Fibroids: Blood Loss and Recurrence. (Abstract)

Laparoscopic Myomectomy with Temporary Bilateral Uterine Artery and Utero-Ovarian Vessels Occlusion Compared with Traditional Surgery for Uterine Fibroids: Blood Loss and Recurrence. To determine the optimal hemostatic technique for laparoscopic myomectomy (LM) by comparing temporary uterine artery blockage alone or combined with blockage of the utero-ovarian vessels.Women with symptomatic uterine myoma attending the Department of Obstetrics and Gynecology in Jinhua Municipal Central Hospital.A (...) total of 200 patients with symptomatic uterine fibroids were randomly divided into Group A (n = 65), Group B (n = 67) and Group C (n = 68). At the beginning of the procedure, 6 U of vasopressin was injected into the myometrium of all women. LM was performed in Group A; temporary bilateral uterine artery occlusion and myomectomy were performed in Group B and temporary bilateral uterine artery and utero-ovarian vessel occlusion was performed in Group C. We then evaluated operative time, perioperative

2019 Gynecologic and obstetric investigation Controlled trial quality: uncertain

29. Uterine Artery Embolisation for Women with Giant Versus Non-giant Uterine Fibroids: A Systematic Review and Meta-analysis. (Abstract)

Uterine Artery Embolisation for Women with Giant Versus Non-giant Uterine Fibroids: A Systematic Review and Meta-analysis. Evidence supporting uterine artery embolisation (UAE) for giant fibroids (≥ 10 cm and/or uterine volume ≥ 700 CC) remains sparse. We performed a systemic review and meta-analysis of UAE outcomes for symptomatic giant versus non-giant fibroids.The literature was systematically reviewed. Research studies of UAE as an adjunct to surgery, and those not using peri-operative MRI (...) were excluded. Primary outcomes were fibroid size and uterine volume reduction, procedure time, length of hospital stay, reinterventions, patient symptom improvement/satisfaction and complications.We identified four observational studies (839 patients; giant = 163, non-giant = 676). Both groups demonstrated reduction in fibroid size and uterine volume after UAE, with equivocal difference in uterine volume reduction (Mean difference (MD) - 0.3 95% confidence interval (CI) - 3.8 to 3.1, p = 0.86

2019 Cardiovascular and interventional radiology

30. Magnetic Resonance-Guided High-Intensity Focused Ultrasound for Treatment of Women with Symptomatic Uterine Fibroids

Magnetic Resonance-Guided High-Intensity Focused Ultrasound for Treatment of Women with Symptomatic Uterine Fibroids Magnetic Resonance –Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE MARCH 2015 Magnetic Resonance –Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation. March 2015; pp. 1 –13 Magnetic Resonance (...) –Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation. March 2015; pp. 1 –13 2 Suggested Citation This report should be cited as follows: Ontario Health Technology Advisory Committee (OHTAC). Magnetic resonance –guided high-intensity focused ultrasound (MRgHIFU) for treatment of symptomatic uterine fibroids: OHTAC recommendation [Internet]. Toronto: Queen's Printer for Ontario; 2015 March. 13 p. Available from: http://www.hqontario.ca

2015 Health Quality Ontario

31. The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility

The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 3, Pages 277–285 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility PRINCIPAL AUTHORS, x Belina Carranza-Mamane , MD Sherbrooke QC x Jon Havelock , MD Vancouver BC x (...) and outcomes with management of fibroids in women with infertility. Evidence Published literature was retrieved through searches of PubMed, MEDLINE, the Cochrane Library in November 2013 using appropriate controlled vocabulary (e.g., leiomyoma, infertility, uterine artery embolization, fertilization in vitro) and key words (e.g., fibroid, myomectomy). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies published in English

2015 Society of Obstetricians and Gynaecologists of Canada

32. The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility

The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility MARCH JOGC MARS 2015 l 277 No. 321, March 2015 SOGC CLINICAL PRACTICE GUIDELINE The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can (...) Tannys Vause, MD, Ottawa ON Benjamin Wong, MD, Calgary AB SPECIAL CONTRIBUTOR Margaret Burnett, MD, Winnipeg MB Disclosure statements have been received from all contributors . Keywords: Female infertility, unexplained infertility, fibroid, leiomyoma, myomectomy, uterine artery embolization, in vitro fertilization, ovarian reserve, ulipristal acetate, magnetic resonance-guided focused ultrasound surgery . J Obstet Gynaecol Can 2015;37(3):277–285 Abstract Objective: To provide recommendations

2015 Society of Obstetricians and Gynaecologists of Canada

33. Interventions for the Management of Symptomatic Uterine Fibroids

Interventions for the Management of Symptomatic Uterine Fibroids Interventions for the Management of Symptomatic Uterine Fibroids | CADTH.ca Find the information you need Interventions for the Management of Symptomatic Uterine Fibroids Interventions for the Management of Symptomatic Uterine Fibroids Published on: July 16, 2015 Project Number: RE0030 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a project on less invasive (...) treatment options for women who suffer from symptomatic uterine fibroids. Uterine fibroids are the most common benign pelvic tumours in women and can have a major impact on women’s health due to abnormal bleeding, pelvic or abdominal pain, and infertility. Surgical removal of the uterus (hysterectomy) is the conventional treatment for symptomatic uterine fibroids. While this can solve some of the problems, hysterectomy is also associated with a high risk of post-operative complications such as pain

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

34. Evidence of biomechanical and collagen heterogeneity in uterine fibroids. (Full text)

Evidence of biomechanical and collagen heterogeneity in uterine fibroids. Uterine fibroids (leiomyomas) are common benign tumors of the myometrium but their molecular pathobiology remains elusive. These stiff and often large tumors contain abundant extracellular matrix (ECM), including large amounts of collagen, and can lead to significant morbidities. After observing structural multiformities of uterine fibroids, we aimed to explore this heterogeneity by focusing on collagen and tissue (...) through the investigation of the complexity of the chemical and biochemical signaling in fibroid development, the correlation of collagen content and mechanical properties in uterine fibroids, and the mechanical forces involved in fibroid development as affected by the various components of the ECM.

2019 PLoS ONE PubMed abstract

35. Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies. (Full text)

Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies. Background: Radiofrequency ablation (RFA) has emerged as a safe and effective treatment option for women with symptomatic uterine fibroids and can be delivered by laparoscopic, transvaginal, or transcervical approaches. The evidence regarding typical patient outcomes with RFA has not previously been examined in a comprehensive fashion. Materials (...) and Methods: We performed a systematic review of prospective studies for treatment of uterine fibroids with RFA. Main outcomes were procedure time, patient recovery metrics, change in fibroid volume, symptom severity score (SSS), health-related quality of life (HRQL), and reinterventions. Data were analyzed with random effects meta-analysis and metaregression. Results: We identified 32 articles of 1283 unique patients (median age: 42 years) treated with laparoscopic RFA (19 articles), transvaginal RFA (8

2020 Journal of laparoendoscopic & advanced surgical techniques. Part A PubMed abstract

36. Magnetic resonance-high intensity focused ultrasound (MR-HIFU) therapy of symptomatic uterine fibroids with unrestrictive treatment protocols: A systematic review and meta-analysis. (Abstract)

Magnetic resonance-high intensity focused ultrasound (MR-HIFU) therapy of symptomatic uterine fibroids with unrestrictive treatment protocols: A systematic review and meta-analysis. Reevaluation of the effectiveness of Magnetic Resonance-High Intensity Focused Ultrasound (MR-HIFU) therapy for uterine fibroids by excluding studies with restrictive treatment protocols that are no longer used.The National Guideline Clearinghouse, Cochrane Library, TRIP, MEDLINE, EMBASE and WHO International (...) Clinical Trials Registry Platform (ICTRP) databases were searched from inception until the 22nd of June 2018. Keywords included "MR-HIFU", "MRgFUS", and "Leiomyoma". Only studies about MR-HIFU treatment of uterine fibroids with at least three months of clinical follow-up were evaluated for inclusion. Treatments with ultrasound-guided HIFU devices or protocols not aiming for complete ablation were eliminated. The primary outcome was the improvement in fibroid-related symptoms. Technical outcomes

2020 European journal of radiology

37. The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies. (Abstract)

The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies. The association between chronic psychological stress and uterine fibroids (UFs) risk remains unclear. In this study, a meta-analysis of observational studies was performed to explore the reported association between them. A literature search was performed in PubMed, EMBASE, and Web of Science to identify relevant published articles. A random-effect model was used to examine

2020 Stress and health : journal of the International Society for the Investigation of Stress

38. Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. (Abstract)

Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. 30580826 2020 03 23 2020 03 23 1701-2163 41 1 2019 01 Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC J Obstet Gynaecol Can Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. 13 S1701-2163(18)30707-2 10.1016/j.jogc.2018.09.011 Odejinmi Funlayo F Barts Health NHS Trust, Whipps Cross Hospital, London, United

2020 Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC

39. Author Response: Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. (Abstract)

Author Response: Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. 30580827 2020 03 23 2020 03 23 1701-2163 41 1 2019 01 Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC J Obstet Gynaecol Can Author Response: Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review. 14 S1701-2163(18)30756-4 10.1016/j.jogc.2018.09.014 Murji Ally A Department of Obstetrics

2020 Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC

40. Intra-abdominal haemorrhage from uterine fibroids: a systematic review of the literature. (Full text)

Intra-abdominal haemorrhage from uterine fibroids: a systematic review of the literature. Uterine leiomyomas are common benign tumours found in women of reproductive age that are rarely associated with intra-abdominal haemorrhage. The aetiology behind this relationship is poorly understood and the aforementioned association poorly recognized from a patient's clinical presentation. Available information in the literature is limited to case reports. The aim of this systematic review (...) is to document and highlight the occurrence of intra-abdominal haemorrhage from uterine fibroids, and determine associated morbidity and mortality.A systematic review of Medline, EMBASE, Web of Science, Scopus, and The Cochrane Library - CENTRAL was performed from the databases inception through to December 2018 for case report and series of patients who experienced intra-abdominal haemorrhage from uterine fibroids. Findings were presented according to the Preferred Reporting Items for Systematic Reviews

2020 BMC Surgery PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>